FDA reviewers back approval of Bayer's lung drug at lower doses

08/4/2013 | Reuters

The FDA should approve Bayer's experimental pulmonary hypertension drug riociguat but at lower doses than what the company sought, the agency's medical reviewers said. The drug, which will be marketed as Adempas once approved, is designed to enhance the exercise ability of patients with chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Corporate Counsel - Regulatory Law
Tarrytown, NY
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
Active Implantable Medical Device (AIMD) Product Expert
Nationwide, SL_Nationwide
Finance Manager - ENT
Jacksonville, FL
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA